Gene Therapy for Parkinson's Disease Market Report 2026

The gene therapy for parkinson’s disease market size has grown exponentially in recent years. It will grow from $0.64 billion in 2025 to $0.81 billion in 2026 at a compound annual growth rate (CAGR) of 26.3%. The growth in the historic period can be attributed to advances in viral vector engineering, increased understanding of parkinson’s disease pathology, expansion of neuroscience research funding, availability of improved delivery technologies, early clinical trial successes.

The gene therapy for parkinson’s disease market size is expected to see exponential growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 26%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease therapies, rising adoption of personalized gene therapy approaches, expansion of late-stage clinical pipelines, growing demand for disease-modifying treatments, advancement of minimally invasive delivery techniques. Major trends in the forecast period include increasing development of viral vector-based therapies, rising focus on dopamine restoration approaches, growing use of neurotrophic factor gene delivery, expansion of precision intracerebral delivery methods, enhanced emphasis on long-term therapeutic efficacy.

The increasing focus on personalized medicine is expected to drive the growth of the gene therapy for Parkinson’s disease market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies based on an individual's genetic profile, lifestyle, and environment. Interest in personalized medicine is rising due to the increasing demand for targeted therapies that enhance treatment efficacy while reducing adverse side effects. Gene therapy for Parkinson’s disease within personalized medicine is employed to deliver customized genetic modifications that restore dopamine function and target patient-specific disease mechanisms. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, a significant increase from the 6 approvals in 2022. Consequently, the growing focus on personalized medicine is fueling the growth of the gene therapy for Parkinson’s disease market.

Major companies are active in the gene therapy for Parkinson’s disease market, concentrating on developing more targeted therapies, such as regenerative medicine advanced therapy, to support neuronal survival, restore dopamine function, and deliver long-lasting disease-modifying effects for patients with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a special designation by the United States Food and Drug Administration (FDA) for regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, intended to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and review of promising therapies, was granted based on data provided by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, showing AB-1005’s potential to slow disease progression and enhance motor function in Parkinson’s patients.

In January 2025, BlackfinBio Limited, a UK-based company offering clinical-stage gene therapy solutions for rare neurological and dopamine-deficiency disorders, acquired the Parkinson’s patent portfolio from Oxford Biomedica plc for an undisclosed amount. With this acquisition, BlackfinBio intends to advance its BFB-201 program for Parkinson’s disease and utilize Oxford Biomedica’s expertise in gene and cell therapy intellectual property to accelerate therapeutic development. Oxford Biomedica plc is a UK-based provider of gene and cell therapy development and vector technologies, contributing valuable intellectual property that complements BlackfinBio’s initiatives.

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene therapy for parkinson’s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene therapy for parkinson’s disease market by increasing costs of imported viral vectors, specialized neurosurgical delivery devices, bioprocessing equipment, and quality control systems. Hospitals, research institutes, and therapy developers in North America and Europe are most affected due to reliance on imported high-precision tools, while Asia-Pacific faces increased production costs. These tariffs are raising therapy development expenses and slowing clinical deployment. However, they are also encouraging domestic vector manufacturing, regional clinical infrastructure investment, and localized production of gene therapy components.

The gene therapy for parkinson’s disease market research report is one of a series of new reports that provides gene therapy for parkinson’s disease market statistics, including gene therapy for parkinson’s disease industry global market size, regional shares, competitors with a gene therapy for parkinson’s disease market share, detailed gene therapy for parkinson’s disease market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy for parkinson’s disease industry. This gene therapy for parkinson’s disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene therapy for Parkinson’s disease involves using genetic methods to insert, repair, or control genes within brain cells. It is intended to restore dopamine production, safeguard nerve cells, or fix mutations linked to the disease. The method aims to slow disease progression and offer long-lasting symptom relief.

The primary therapy types of gene therapy for Parkinson’s disease are in vivo gene therapy and ex vivo gene therapy. In vivo gene therapy involves the direct administration of genetic material into the patient’s body, usually via viral or non-viral vectors, to restore or enhance the function of specific genes associated with the progression of Parkinson’s disease. These therapies focus on genes such as aromatic L-amino acid decarboxylase (AADC), glial cell line-derived neurotrophic factor (GDNF), neurturin, and other related genes, and are delivered through methods including intracerebral, intravenous, and other approaches. The main end-users include hospitals, specialty clinics, research institutes, and similar entities.

The gene therapy for parkinson’s disease market consists of revenues earned by entities by providing services such as genetic counseling, preclinical studies, clinical trial management, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy for parkinson’s disease market also includes sales of viral vectors, aromatic L-amino acid decarboxylase (AADC) gene therapy, glutamic acid decarboxylase (GAD) gene therapy, glial cell line-derived neurotrophic factor (GDNF) or neurturin-based neurotrophic therapies, and glucocerebrosidase (GBA)-targeted gene therapies. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.